{"id":52378,"date":"2025-12-31T20:59:50","date_gmt":"2025-12-31T12:59:50","guid":{"rendered":"https:\/\/flcube.com\/?p=52378"},"modified":"2025-12-31T20:59:51","modified_gmt":"2025-12-31T12:59:51","slug":"zelgen-licenses-zg006-to-abbvie-for-1-2-billion-in-milestones-ex-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52378","title":{"rendered":"Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China"},"content":{"rendered":"\n<p><strong>Suzhou Zelgen Biopharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688266:SHA\">SHA: 688266<\/a>) announced a <strong>strategic collaboration and licensing option agreement<\/strong> with <strong>AbbVie Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ABBV:NYSE\">NYSE: ABBV<\/a>) for the global development and commercialization of <strong>ZG006 (Alveltamig)<\/strong>, a <strong>novel trispecific T-cell engager targeting DLL3<\/strong> for <strong>small cell lung cancer (SCLC)<\/strong> and other DLL3-expressing malignancies. AbbVie gains exclusive rights outside Greater China while Zelgen retains domestic rights.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-overview\">Deal Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Suzhou Zelgen Biopharmaceuticals (688266.SH)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>AbbVie Inc. (NYSE: ABBV)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>ZG006 (Alveltamig) \u2013 trispecific T-cell engager (TCE)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>DLL3 (Delta-like ligand 3)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Ex-Greater China (excludes Mainland China, Hong Kong, Macau)<\/td><\/tr><tr><td><strong>Structure<\/strong><\/td><td>Strategic collaboration + licensing option<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>Small cell lung cancer (SCLC) and other DLL3-expressing cancers<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-terms-amp-value-creation\">Financial Terms &amp; Value Creation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Amount<\/th><th>Structure<\/th><\/tr><\/thead><tbody><tr><td><strong>Initial Payment<\/strong><\/td><td>USD\u202f100\u202fmillion<\/td><td>Upfront, non-refundable<\/td><\/tr><tr><td><strong>Progress Payments<\/strong><\/td><td>Up to USD\u202f60\u202fmillion<\/td><td>Tied to clinical milestones &amp; licensing option exercise<\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>Up to USD\u202f1.075\u202fbillion<\/td><td>Upon AbbVie exercising option (regulatory &amp; commercial)<\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td><strong>Up to USD\u202f1.235\u202fbillion<\/strong><\/td><td>Excluding royalties<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td><strong>High\u2011single to mid\u2011double digits<\/strong><\/td><td>Tiered on net sales ex\u2011Greater China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Royalties Only on Ex\u2011China Sales<\/strong>: Zelgen retains <strong>100% of economics<\/strong> in Greater China, projected to represent <strong>25\u201130%<\/strong> of global DLL3\u2011targeting market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-zg006-alveltamig\">Product Profile: ZG006 (Alveltamig)<\/h2>\n\n\n\n<p><strong>Technology<\/strong>: <strong>Trispecific T\u2011cell engager (TCE)<\/strong> designed to redirect T cells to DLL3\u2011expressing tumor cells via simultaneous CD3 and dual DLL3 binding domains.<\/p>\n\n\n\n<p><strong>Regulatory Status<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>FDA<\/strong>: Clinical trial approval granted; <strong>Orphan Drug Designation<\/strong> received<\/li>\n\n\n\n<li><strong>NMPA<\/strong>: Clinical trial approval granted<\/li>\n\n\n\n<li><strong>CDE Breakthrough Therapy Designation<\/strong>: For <strong>relapsed\/progressive advanced SCLC<\/strong> and <strong>DLL3\u2011positive neuroendocrine carcinoma<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Development Stage<\/strong>: <strong>Late\u2011stage clinical development<\/strong>; pivotal trials ongoing in US and China.<\/p>\n\n\n\n<p><strong>Market Significance<\/strong>: DLL3 is expressed in <strong>&gt;80% of SCLC tumors<\/strong> and <strong>neuroendocrine carcinomas<\/strong>, with <strong>no approved targeted therapies<\/strong> beyond chemotherapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-dll3-targeting-landscape\">Market Opportunity: DLL3\u2011Targeting Landscape<\/h2>\n\n\n\n<p><strong>Small Cell Lung Cancer (SCLC) Market<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Incidence<\/strong>: <strong>250,000<\/strong> new cases annually (US: 35,000; China: 70,000)<\/li>\n\n\n\n<li><strong>5\u2011Year Survival<\/strong>: <strong>7%<\/strong> for extensive\u2011stage disease; <strong>massive unmet need<\/strong><\/li>\n\n\n\n<li><strong>Current Standard<\/strong>: Platinum\u2011based chemotherapy + immunotherapy (limited duration of response)<\/li>\n<\/ul>\n\n\n\n<p><strong>Addressable Market<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ex\u2011China Market<\/strong>: <strong>\u00a535\u201140\u202fbillion<\/strong> (US$5\u20116\u202fbillion) peak potential by 2032<\/li>\n\n\n\n<li><strong>China Market<\/strong>: <strong>\u00a512\u201115\u202fbillion<\/strong> (US$1.7\u20112.1\u202fbillion) peak potential<\/li>\n\n\n\n<li><strong>Target Population<\/strong>: <strong>Refractory\/relapsed SCLC<\/strong> patients post\u20111L therapy (eligible for ZG006)<\/li>\n<\/ul>\n\n\n\n<p><strong>Neuroendocrine Carcinoma Expansion<\/strong>: Additional <strong>50,000<\/strong> patients annually ex\u2011China, representing <strong>30%<\/strong> upside to SCLC\u2011only opportunity.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Company<\/th><th>Mechanism<\/th><th>Stage<\/th><th>Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>ZG006<\/strong><\/td><td><strong>Zelgen \u2192 AbbVie<\/strong><\/td><td>Trispecific TCE (DLL3 x CD3)<\/td><td>Phase\u202fIII<\/td><td><strong>Trispecific<\/strong> design; <strong>Breakthrough\/OOD<\/strong> status<\/td><\/tr><tr><td><strong>Tarlatamab<\/strong><\/td><td>Amgen<\/td><td>Bispecific TCE (DLL3 x CD3)<\/td><td>Phase\u202fIII (US)<\/td><td><strong>Bispecific<\/strong>; PDUFA date Q2\u202f2026<\/td><\/tr><tr><td><strong>Rovalpituzumab<\/strong><\/td><td>AbbVie (legacy)<\/td><td>ADC (DLL3)<\/td><td><strong>Terminated<\/strong> (MERU trial failed)<\/td><td>Historical failure creates need<\/td><\/tr><tr><td><strong>Rova\u2011T<\/strong><\/td><td>AbbVie (legacy)<\/td><td>ADC (DLL3)<\/td><td><strong>Terminated<\/strong><\/td><td>Reinforces TCE approach<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Strategic Position<\/strong>: ZG006\u2019s <strong>trispecific architecture<\/strong> may offer <strong>improved avidity<\/strong> and <strong>reduced toxicity<\/strong> vs. Amgen\u2019s bispecific tarlatamab, positioning it as a <strong>best\u2011in\u2011class<\/strong> contender.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-amp-synergies\">Strategic Rationale &amp; Synergies<\/h2>\n\n\n\n<p><strong>For Zelgen<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Non\u2011Dilutive Capital<\/strong>: <strong>USD\u202f160\u202fmillion<\/strong> upfront\/progress payments fund China development without equity raise<\/li>\n\n\n\n<li><strong>Ex\u2011China Leverage<\/strong>: AbbVie\u2019s <strong>global oncology infrastructure<\/strong> (2,000+ reps) accelerates ex\u2011China commercialization<\/li>\n\n\n\n<li><strong>Risk Mitigation<\/strong>: Retains <strong>Greater China rights<\/strong> in highest\u2011growth market while monetizing rest of world<\/li>\n<\/ul>\n\n\n\n<p><strong>For AbbVie<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Gap Fill<\/strong>: Replaces failed <strong>Rova\u2011T<\/strong> and complements <strong>Imbruvic<\/strong> etirement with <strong>next\u2011gen oncology asset<\/strong><\/li>\n\n\n\n<li><strong>Late\u2011Stage Asset<\/strong>: Phase\u202f3\u2011ready program reduces <strong>time\u2011to\u2011market<\/strong> vs. internal discovery<\/li>\n\n\n\n<li><strong>China Optionality<\/strong>: Option structure allows <strong>strategic flexibility<\/strong> pending clinical data readout<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-amp-commercialization-timeline\">Development &amp; Commercialization Timeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Target Date<\/th><th>Responsibility<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase\u202f3 Initiation<\/strong><\/td><td>Q1\u202f2026 (US), Q2\u202f2026 (China)<\/td><td>Zelgen (China), AbbVie (ex\u2011China)<\/td><\/tr><tr><td><strong>Pivotal Data Readout<\/strong><\/td><td>H2\u202f2027 (SCLC)<\/td><td>Shared development committee<\/td><\/tr><tr><td><strong>FDA\/EMA NDA Filing<\/strong><\/td><td>Q1\u202f2028 (if positive)<\/td><td>AbbVie (ex\u2011China)<\/td><\/tr><tr><td><strong>NMPA NDA Filing<\/strong><\/td><td>Q2\u202f2028 (China)<\/td><td>Zelgen<\/td><\/tr><tr><td><strong>Commercial Launch<\/strong><\/td><td>2029 (ex\u2011China), 2029\u20112030 (China)<\/td><td>AbbVie\/Zelgen respective territories<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding ZG006\u2019s clinical development, regulatory approvals, market opportunity, and financial contributions to Zelgen and AbbVie. Actual results may differ materially due to clinical trial outcomes, competitive dynamics, regulatory review timelines, and market access challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/688266_20260101_CN11.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688266_20260101_CN11.\"><\/object><a id=\"wp-block-file--media-23e4c97c-e087-4e02-8bd1-a3de80c19e90\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/688266_20260101_CN11.pdf\">688266_20260101_CN11<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/688266_20260101_CN11.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-23e4c97c-e087-4e02-8bd1-a3de80c19e90\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced a strategic collaboration and licensing option agreement&#8230;<\/p>\n","protected":false},"author":1,"featured_media":52380,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[234,16,853,905,2790,246],"class_list":["post-52378","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-abbvie","tag-cancer","tag-nyse-abbv","tag-sha-688266","tag-t-cell-engager","tag-zelgen-biopharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced a strategic collaboration and licensing option agreement with AbbVie Inc. (NYSE: ABBV) for the global development and commercialization of ZG006 (Alveltamig), a novel trispecific T-cell engager targeting DLL3 for small cell lung cancer (SCLC) and other DLL3-expressing malignancies. AbbVie gains exclusive rights outside Greater China while Zelgen retains domestic rights.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=52378\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China\" \/>\n<meta property=\"og:description\" content=\"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced a strategic collaboration and licensing option agreement with AbbVie Inc. (NYSE: ABBV) for the global development and commercialization of ZG006 (Alveltamig), a novel trispecific T-cell engager targeting DLL3 for small cell lung cancer (SCLC) and other DLL3-expressing malignancies. AbbVie gains exclusive rights outside Greater China while Zelgen retains domestic rights.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=52378\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-31T12:59:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-31T12:59:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3101-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52378#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52378\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China\",\"datePublished\":\"2025-12-31T12:59:50+00:00\",\"dateModified\":\"2025-12-31T12:59:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52378\"},\"wordCount\":652,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52378#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/3101-1.webp\",\"keywords\":[\"AbbVie\",\"Cancer\",\"NYSE: ABBV\",\"SHA: 688266\",\"T cell engager\",\"Zelgen Biopharmaceuticals\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52378#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52378\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=52378\",\"name\":\"Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52378#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52378#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/3101-1.webp\",\"datePublished\":\"2025-12-31T12:59:50+00:00\",\"dateModified\":\"2025-12-31T12:59:51+00:00\",\"description\":\"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced a strategic collaboration and licensing option agreement with AbbVie Inc. (NYSE: ABBV) for the global development and commercialization of ZG006 (Alveltamig), a novel trispecific T-cell engager targeting DLL3 for small cell lung cancer (SCLC) and other DLL3-expressing malignancies. AbbVie gains exclusive rights outside Greater China while Zelgen retains domestic rights.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52378#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52378\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52378#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/3101-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/3101-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52378#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China - Insight, China&#039;s Pharmaceutical Industry","description":"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced a strategic collaboration and licensing option agreement with AbbVie Inc. (NYSE: ABBV) for the global development and commercialization of ZG006 (Alveltamig), a novel trispecific T-cell engager targeting DLL3 for small cell lung cancer (SCLC) and other DLL3-expressing malignancies. AbbVie gains exclusive rights outside Greater China while Zelgen retains domestic rights.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=52378","og_locale":"en_US","og_type":"article","og_title":"Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China","og_description":"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced a strategic collaboration and licensing option agreement with AbbVie Inc. (NYSE: ABBV) for the global development and commercialization of ZG006 (Alveltamig), a novel trispecific T-cell engager targeting DLL3 for small cell lung cancer (SCLC) and other DLL3-expressing malignancies. AbbVie gains exclusive rights outside Greater China while Zelgen retains domestic rights.","og_url":"https:\/\/flcube.com\/?p=52378","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-31T12:59:50+00:00","article_modified_time":"2025-12-31T12:59:51+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3101-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=52378#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=52378"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China","datePublished":"2025-12-31T12:59:50+00:00","dateModified":"2025-12-31T12:59:51+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=52378"},"wordCount":652,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=52378#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3101-1.webp","keywords":["AbbVie","Cancer","NYSE: ABBV","SHA: 688266","T cell engager","Zelgen Biopharmaceuticals"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=52378#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=52378","url":"https:\/\/flcube.com\/?p=52378","name":"Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=52378#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=52378#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3101-1.webp","datePublished":"2025-12-31T12:59:50+00:00","dateModified":"2025-12-31T12:59:51+00:00","description":"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced a strategic collaboration and licensing option agreement with AbbVie Inc. (NYSE: ABBV) for the global development and commercialization of ZG006 (Alveltamig), a novel trispecific T-cell engager targeting DLL3 for small cell lung cancer (SCLC) and other DLL3-expressing malignancies. AbbVie gains exclusive rights outside Greater China while Zelgen retains domestic rights.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=52378#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=52378"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=52378#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3101-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3101-1.webp","width":1080,"height":608,"caption":"Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=52378#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3101-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52378","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52378"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52378\/revisions"}],"predecessor-version":[{"id":52381,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52378\/revisions\/52381"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/52380"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52378"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52378"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52378"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}